Prevention

Taking the pulse: Understanding CV risk in Type II diabetes

6 COMMENTS - Aug 8, 2008 11:23 EDT

Type 2 diabetes mellitus (T2DM) increases the risk of CVD. What is the role of the cardiologist in helping to reduce CV risk in people with T2DM.

Prevention

There is a need for effective risk stratification... where do biomarkers fit in?

12 COMMENTS - Jul 17, 2008 09:29 EDT

The majority of physicians agree there is a need for effective risk stratification to enable early, accurate and cost-effective identification of those individuals who would benefit from therapeutic interventions. However, there is a lack of consensus on the use and utility of novel assessment tools that may identify at-risk patients and provide valuable surrogate endpoints. Please share with us your thoughts on the use of biomarkers in clinical care.

Clinical cardiology

Current trends in cardiac resynchronization therapy

Jun 27, 2008 09:49 EDT

Join Drs Linde, Daubert and Gold in an intriguing discussion on the impact of cardiac resynchronization therapy on remodeling and disease progression, with a review of new data by Dr Abraham.

Prevention

Human genomics: What does the cardiologist need to know?

9 COMMENTS - Jun 25, 2008 09:30 EDT

Are you hip to SNPs? Dr Eric Topol discusses the identification of genetic variants associated with an increased risk for cardiovascular disease and their potential application to patient management. You can also download Dr Christopher Granger's PowerPoint overview of genetics for the cardiologist.

Prevention

CV prevention: Another look at stories of 2007-the year in review

Mar 11, 2008 12:00 EDT

Drs Weber and Nissen run down and give perspective to heartwire stories on the topic of prevention that were the most important in 2007. Which stories give evidence of progress and which stories have proven controversial? Enjoy their fast moving commentary.

Prevention

Inhibitors of the RAS: Many meta-analyses - but no one answer

1 COMMENT - Feb 29, 2008 16:00 EST

ACEs, ARBs, combinations. Which is best? Drs Weber, Kostis, Messerli and Gradman discuss recent meta-analyses. Is there a definitive winner?

Prevention

CKD and CVD: Examining strategies for target organ protection and CV risk reduction

Nov 27, 2007 16:00 EST

From the bench to the bedside: Old and new markers of target organ disease advance the understanding of chronic kidney disease, but what are the strategies that are now being tested in the clinic? Drs Ibrahim, Gansevoort and Tobe discuss advances in chronic kidney disease and how it translates to reducing cardiovascular outcomes.

Prevention

ACEs and ARBs: Show me the evidence in stroke and atrial fibrillation

Nov 21, 2007 17:30 EST

Are all RAAS inhibitors created equal? Drs Smith, Kowey and Weber discuss outcome results that do not necessarily follow the norm.

Prevention

ACEs and ARBs: Show me the evidence in diabetes and heart failure

1 COMMENT - Nov 21, 2007 14:30 EST

Life saving drugs: Is one RAAS blocker better than others? Are two better than either one? How can we make the right choice for the patient? Do we have the data to support clinical decisions?

Prevention

High risk cardiovascular disease

Oct 19, 2007 13:15 EDT

Risks, trials and treatments discussed at ESC symposia. Highlights and synopsis of key symposia.

Prevention

An ONTARGET global view of high risk cardiovascular disease

10 COMMENTS - Sep 18, 2007 10:00 EDT

Many uncertainties still abound about optimal management of patients at high risk for CV events. The ONTARGET trial is the most ambitious attempt to find the right answers.

Prevention

Slides and resources

2 COMMENTS - Jul 16, 2007 16:30 EDT

This new resource center is conceived to provide key articles, slide kits and support material to physicians and healthcare providers involved in the care of patients presenting with any of the cardiovascular risks. This is a site that offers information and data you may not easily find elsewhere! Take advantage of this tool and learn more about cardiovascular risks.

Prevention

Hypertension and beyond: Highlights from ESH 2007

Jun 29, 2007 12:00 EDT

Hear what the experts have to say about ESH 2007: Join Dr Weber as he discusses topics ranging from microalbuminuria, cardiovascular risk and the new ESH/ESC Hypertension Guidelines with Drs Mancia, Hermida, Meredith, Schmeider, Collier and Lacy.

Prevention

Preventing cardiovascular and renal disease: A clinical update

3 COMMENTS - Jun 22, 2007 15:00 EDT

Angiotensin receptor blockers (ARBs) not only provide blood pressure control but also have important blood pressure-independent benefits. Please join Drs Mancia, Burgess and McInnes as they discuss how ARBs may help to address total cardiovascular risk across the cardiovascular continuum.

Prevention

ACEIs, ARBs and renin inhibitors: How best to block the RAS?

Jun 14, 2007 07:00 EDT

Clinicians now have 3 alternatives to block the complex Renin-Angiotensin-System, as well as the option of combining agents. Does it really matter which option is used? A panel discussion examines this question with Drs Weber, Dzau, Gorelick, and Hollenberg.

Prevention

Heart rate as a marker for cardiovascular disease

Jun 6, 2007 14:15 EDT

There has been much discussion regarding the importance of heart rate (HR) as a prognostic index of cardiovascular risk. Recent data strongly suggest that the beneficial effects of drug treatment, in areas such areas as postmyocardial infarction prophylaxis and heart failure, may be due to its ability to reduce HR. The exact mechanism(s) by which a HR under control confers its protection to the myocardium has yet to be elucidated, but may be related to hemodynamic stabilization that may reduce the pathogenesis of plaque disruption and also be anti-ischaemic, antiarrhythmic and anti-atherosclerotic.

Prevention

Late-breaking: The AMADEO trial - a head-to-head comparison of ARBs

3 COMMENTS - May 30, 2007 10:22 EDT

The AMADEO trial: The very first head-to-head comparison of ARBs for differences in proteinuria or kidney disease progression. See how reducing blood pressure in hypertensive diabetics can benefit the kidneys.

Prevention

CV Risks Prevention theme background and educational mission

May 18, 2007 18:30 EDT

As the population ages and the prevalence of hypertension increases worldwide, clinicians need to recognize that poorly controlled hypertension leads to the development of cardiovascular disease. Clinicians must remain up-to-date with best practices in the management of hypertension as ways to improve patient awareness, compliance and prevention of comorbidities.

Prevention

The relationship between CKD and CVD: Update in target organ protection and cardiovascular risk reduction

May 18, 2007 18:00 EDT

Chronic kidney disease and cardiovascular disease: Double trouble leads to more morbidity and mortality. What new therapies offer promise for patients with chronic kidney disease?

Prevention

Addressing the CVD Epidemic

Mar 19, 2007 12:12 EDT

Cardiovascular (CV) disease is the single leading cause of death in the United States. Multiple risk factors such as hypertension, diabetes, obesity, and dyslipidemia contribute to multiple pathophysiologic/neurohormonal processes that affect the development of CV disease. This program will review current and emerging approaches to CV risk management. CME Provider: The Academy for Healthcare Education, Inc. Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

	General cardiologist
	Interventional cardiologist
	Internal medicine physician
	Primary care physician
	Cardiovascular surgeon
	Other physician